Trade Summary

6 days ago, Happel David, serving as President & CEO at Sagimet Biosciences Inc. (SGMT), sold 64,051 shares at $7.76 per share, for a total transaction value of $497,067.79. Following this transaction, Happel David now holds 741,570 shares of SGMT.

This sale represents a 7.95% decrease in Happel David's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, July 20, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, July 22, 2026 at 4:05 PM ET, 2 days after the trade was made.

Sagimet Biosciences Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.